CSS expands capability in specialist manufacturing

The integration of the peptide and protein business of Albachem within CSS has already led to benefits for pharma and biotech companies, according to David Moody, vp commercial operations. The company's POP proprietary synthesis and purification techniques allow easy access to chemically synthesised long proteins (up to 170 amino acids) with all the advantages of speed and purity previously possible only with much smaller peptides. A major consequence of this integration is the offering of small-scale cGMP manufacture of peptides, oligonucleotides and proteins.

CSS has also expanded its potent and cytotoxic manufacturing and micronisation capabilities following successful commissioning of new facilities in Northern Ireland, enabling the production of Highly Active Pharmaceutical Ingredients (HAPI), cytotoxics and cytotoxic conjugates.